Watson, Sandoz settle Medicaid whistleblower suits for $145M

Watson Pharmaceuticals ($WPI) and Novartis' ($NVS) generics unit Sandoz have agreed to settle False Claims Act lawsuits alleging  they overstated the prices on drugs sold to Medicaid programs. Watson agreed to pay $79 million, and Sandoz will cough up $66 million. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.